BioNTech Results Presentation Deck
Q2 and H1 2022 Financial Results - Profit or Loss
Three months ended
June 30,
(in millions, except per share data)¹
Commercial revenues²
Research & development revenues
Total revenues
Cost of sales
Research and development expenses
Sales and marketing expenses
General and administrative expenses
Other operating income less expenses
Operating income
Finance income less expenses
Income taxes
Profit for the period
Earnings per share
Basic profit for the period per share
Diluted profit for the period per share
2022
€3,166.3
30.2
€3,196.5
(764.6)
(399.6)
(17.8)
(130.0)
325.1
€2,209.6
109.7
(647.3)
€1,672.0
€6.86
€6.45
2021
€5,280.5
28.0
€5,308.5
(883.8)
(201.1)
(13.3)
(47.8)
35.9
€4,198.4
(175.6)
(1,235.6)
€2,787.2
€11.42
€10.77
Six months ended
June 30,
2022
€9,528.5
42.6
€9,571.1
(2,058.7)
(685.4)
(32.1)
(220.8)
388.2
€6,962.3
375.1
(1,966.6)
€5,370.8
€22.00
€20.69
1 Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context. Presentation of the consolidated statements of profit or loss
has been condensed.
25
2 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021 as
well as the Quarterly Report as of and for the three and six months ended June 30, 2022, filed as an exhibit to BioNTech's Current Report on Form 6-K filed on August 8, 2022. Any changes in the
estimated share of the collaboration partner's gross profit will be recognized prospectively.
2021
€7,308.0
48.9
€7,356.9
(1,116.9)
(417.3)
(22.0)
(86.7)
146.6
€5,860.6
(195.5)
(1,749.8)
€3,915.3
€16.07
€15.14
BIONTECHView entire presentation